Capsule Presentation

Each hard gelatin capsule contains:
Rabeprazole Sodium IP 20 mg
Domperidone BP 30 mg


This is a combination contains Domperidone and Rabeprazole. Domperidone is a prokinetic which works on the upper digestive tract to increase the peristaltic movement, allowing the food to move more easily through the stomach. Rabeprazole is a proton pump inhibitor (PPI) act by inhibiting production of gastric acid in the stomach which helps in the relief of acid-related indigestion and heartburn.

Indications

  • Gastroesophageal reflux disease (GERD)
  • Zollinger-Ellison Syndrome
  • Peptic ulcer
  • Erosive Esophagitis (EE)
  • Bacterial Infection Due to Helicobacter Pylori

Mechanism of Action

Rabeprazole decreases gastric acid production.Rabeprazole may also be used in H. pylori infection along with antibiotics that are associated with gastric ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. Rabeprazole is absorbed from GIT with a bioavailability of about 52%. Rabeprazole shows 96.3% of plasma protein binding and is extensively metabolised in liver. Approximately 90% of the drug was eliminated in the urine and the half-life is 1-2 hours in plasma.

Domperidone is a specific blocker of dopamine receptors. It increases peristaltic moment, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Domperidone blocks D2 and D3 dopamine receptors present in chemoreceptor trigger zone and shows antiemetic property. It has strong affinities for the, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting. Domperidone is rapidly absorbed from GIT and the bioavailability is only 20% due to high first pass metabolism. 91%-93% of the dose administered is bound to plasma protein with a half-life of 7 hours. The metabolites are mainly excreted in urine and feces.

Side Effects

  • Diarrhea
  • Stomach pain
  • Flatulence
  • Dryness in mouth
  • Dizziness
  • Headache

Precaution

  • Carefully use in patients with renal and hepatic impairment
  • Hypersensitivity can occur in patient with phaeochromocytoma
  • Systemic lupus erythematosus
Know About new DCGI Approved Products